Yourgene Health Share Discussion Threads

[melton john] 23/11/2022 11:53

real spread is 2.05=2.18 for 125000
For that size and just that spread the MM's make £162.5 for the deal.
Don't get confused by the advertised spread look at prices of trades.
For buying 400000 I was quoted 2.34p

[melton john] 23/11/2022 09:23

Real spread for 150k = 2.09-2.2p

[best1467] 23/11/2022 09:22

A reassuring RNS stating no need for cash call and see no reason for 500% share drop since May. Would be welcomed

[apad] 23/11/2022 08:29

Keep the sensible dialogue going and ignore the trolls you two 😇

I need the comfort of other folks agreeing with me 😊

apad

[melton john] 23/11/2022 08:15

Good to see some buying at 2.23p . Got to be a good bet

[melton john] 23/11/2022 07:45

Catch, forget the tripe comment, which related to the many other negative with no evidence posts. I was trying to point out that the size of the fall was artificially exaggerated by manipulating the closing price. There appears to be a concerted effort to talk down the price and ignore any positives which your first short post seemed to support. Thanks for enlarging on it and I agree with the points in your last.

[catch007] 22/11/2022 23:49

Melton John: I felt 13% fall in share price was indeed a steep fall, hardly describe that as tripe. My question was posed to elicit some sensible views re the current position especially around the cash position which was not stated in recent TU.

I was and remain positive around Ranger applications. The core YGEN business model is a volume orientated testing play so recent US partnerships need to deliver in H2 to generate cash. I really see little value or merit in discussing whether opening or closing prices re 2.5p or 2.6p both are irrelevant, more valuable is the future direction of travel of YGEN share price Like you I am a LTH of YGEN I may add again once more certainty is available however despite your Stockopedia data (thank you) there remains much confusion and conjecture at present as to the true prospects of the company at present.

[melton john] 22/11/2022 22:49

organstop, price manipulation going on to prompt selling.

[melton john] 22/11/2022 22:45

Catch007,
Steep fall today if you believe the closing price yesterday was realistic based on a UT of £220 worth at 2.6p in the final auction when the price hadn't gone above 2.50 all day. This determined the opening price today and helped show a bigger drop. Lambs to the slaughter allowing some meaty buys today. Cash flow isn't great but they had over £4M cash at the interim, near breaking even with a £226k loss and reducing outgoings. Why dilute with a placing when debt is only 600k, Did you watch this video of the lady talking about Ranger, that sounds like a better mousetrap with many applications.

www.brrmedia.co.uk/broadcasts/636a5d5473b22f035bb813c3/yourgene-health-interview-with-dr-joanne-mason/

Such a lot of tripe posted on this thread by some.

[organstop] 22/11/2022 22:17

But the trades show as practically all buys -?

[birdie12] 22/11/2022 17:24

TW posting about the dangers of leaving a placing too late.

[birdie12] 22/11/2022 17:23

or smokin' summat?

[mr macgregor] 22/11/2022 17:12

GLT on the G&T?

[amanitaangelicus] 22/11/2022 16:38

Terminal ...run while you can ...

[birdie12] 22/11/2022 16:21

not according to GLT on the other BB. Not too far off maybe in his calcs?

''The tech validation process takes time in our business / category.
Eyes will be on us given various university research results, plus Labcorp, Ambry and 2 other megalabs. I wouldn't be surprised if takeover is being discussed already at buyco level (business case) and then swoop.
Re finances, we had £8.4m as at 31 March 2022.
We already know we are on track to deliver FY revenue expectations, with based on the comment of "£9.6m being over 40% of FY revenue" indicate anywhere between £21.3n - £22.3m I reckon. @ GP% of say 56%, we have circa £12 - £12.5m GP. The savings of £5m is approximately 1/3 of total OPEX, so say OPEX in FY2023 is £13m (ie not full year savings) + one off restructuring of £0.5m, we are then -£1m EBITDA.
Given the comments from company, they will manage WC and discretionary investment IF needed. So, assuming they counter each other, the loan repayment of £1.7m + interest = £2m.
This leaves year end cash balance of £5.4m.......and for prudence, say £4m!
We then expect to turn EBITDA +ve in FY2024 and that should fund loan repayment and investment (if needed).
If we generate 30% growth in FY2024, that will deliver £5m EBITDA assuming same margins, full year savings and no more one-offs. So, I don't see why we need more cash!
And if we are growing Ranger + NIPT significantly in US, we can get financing for growth another way.
As I previously said, Ambry revenues should be in excess of $5m alone''!

[catch007] 22/11/2022 14:44

Another relatively steep % fall today. I am surmising it is cashflow issues?

[melton john] 18/11/2022 19:34

We agree there, I hope you had a little top up. Definite big buying today, no fiddling with the spread to try and fool us whether buys or sells. All it needs is to sit on our hands and ignore attempts to make us sell. They'll be short of shares at some time, they wouldn't want to hold a lot in a falling market I reckon.

[timojelly] 18/11/2022 19:16

Massively undervalued imo.

[melton john] 18/11/2022 16:49

Do tell us more, I don't get your point.

[best1467] 18/11/2022 08:58

Melton The keyboard warrior

[birdie12] 17/11/2022 19:42

a bit more time needed..next 6/12 months will do the trick..lol

[timojelly] 17/11/2022 19:25

Well, it appears 'enhancing shareholder value ' has gone straight out of the window.